In this sense, the clear contribution of the ERK1/2 signaling pathway in psoriasis led us to target one of its downstream effectors, the ribosomal s6 kinase (RSK), and to evaluate the effect of its inhibition on the PS+T morphology. This evidence concerns the gene MAPK3 and psoriasis.